Pfizer (NYSE:PFE) is scheduled to be posting its quarterly earnings results before the market opens on Monday, January 29th. Pfizer has set its FY17 guidance at $2.58-2.62 EPS.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period last year, the firm posted $0.61 earnings per share. The business’s revenue was up .9% on a year-over-year basis. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of Pfizer (NYSE:PFE) opened at $36.94 on Monday. Pfizer has a 52-week low of $30.90 and a 52-week high of $37.37. The stock has a market capitalization of $220,190.00, a P/E ratio of 22.66, a PEG ratio of 2.30 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.68%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,450 shares of company stock worth $1,065,220. Corporate insiders own 0.06% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Beach Investment Management LLC. bought a new position in shares of Pfizer in the 2nd quarter valued at $5,214,000. Hanson McClain Inc. increased its stake in shares of Pfizer by 2.0% in the 2nd quarter. Hanson McClain Inc. now owns 13,898 shares of the biopharmaceutical company’s stock valued at $467,000 after purchasing an additional 276 shares during the last quarter. Alpha Omega Wealth Management LLC increased its stake in shares of Pfizer by 3.4% in the 2nd quarter. Alpha Omega Wealth Management LLC now owns 108,815 shares of the biopharmaceutical company’s stock valued at $3,655,000 after purchasing an additional 3,534 shares during the last quarter. Usca Ria LLC increased its stake in shares of Pfizer by 0.3% in the 2nd quarter. Usca Ria LLC now owns 332,964 shares of the biopharmaceutical company’s stock valued at $11,184,000 after purchasing an additional 1,033 shares during the last quarter. Finally, Intrust Bank NA increased its stake in shares of Pfizer by 2.5% in the 2nd quarter. Intrust Bank NA now owns 65,268 shares of the biopharmaceutical company’s stock valued at $2,192,000 after purchasing an additional 1,596 shares during the last quarter. Hedge funds and other institutional investors own 69.75% of the company’s stock.
Several research firms recently weighed in on PFE. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Wednesday, January 17th. Morgan Stanley set a $41.00 price target on Pfizer and gave the stock a “buy” rating in a report on Friday, January 5th. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, January 8th. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price target for the company. in a report on Monday, January 15th. Finally, Jefferies Group set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average price target of $38.12.
ILLEGAL ACTIVITY NOTICE: “Pfizer (PFE) Set to Announce Earnings on Monday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/22/pfizer-pfe-set-to-announce-earnings-on-monday.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.